Sub 20 nm Upconversion Photosensitizers for Near‐Infrared Photodynamic Theranostics

Anne Nsubuga; Korentin Morice; Nour Fayad; Federico Pini; Véronique Josserand; Xavier Le Guével; Abdallah Alhabi; Maxime Henry; Dario Puchán Sánchez; Nathan Plassais; Pierre Josse; Julien Boixel; Philippe Blanchard; Clément Cabanetos; Niko Hildebrandt

doi:10.1002/adfm.202410077

journal article·2025-01Open access

Sub 20 nm Upconversion Photosensitizers for Near‐Infrared Photodynamic Theranostics

Anne Nsubuga, Korentin Morice, Nour Fayad, Federico Pini, Véronique Josserand, Xavier Le Guével, Abdallah Alhabi, Maxime Henry, Dario Puchán Sánchez, Nathan Plassais, Pierre Josse, Julien Boixel, Philippe Blanchard, Clément Cabanetos, Niko Hildebrandt

Advanced Functional Materials· Volume 35· Issue 1

Publisher page Open full text

Source abstract

Abstract

Abstract Efficient type II photodynamic therapy (PDT) requires stable and biocompatible photosensitizers (PS) that present low dark cytotoxicity, are photo‐excitable in deep tissue regions, and can efficiently penetrate and kill cells via in situ singlet oxygen production. Here, heavy‐metal‐free organic PS are combined with near‐infrared (NIR)‐excitable small (<20 nm) upconversion nanoparticles (UCNPs) into UCNP‐PS nanohybrids for accomplishing such advanced PDT conditions. UCNP‐to‐PS energy transfer efficiencies between 11% and 42% and ¹O₂ generation quantum yields between 74% and 86% resulted in efficient NIR‐sensitized PDT. HeLa cells incubated with UCNP‐PS can be efficiently destroyed via 808 nm laser irradiance at 140 mW cm⁻² for 3 min (<30% cell viability) or 3.2 W cm⁻² for 6 min (<10% cell viability). Theranostic functionality of UCNP‐PS is demonstrated via live cell in situ imaging of intracellular UCNP‐PS‐mediated ¹O₂ production, which resulted in cell death, most probably via apoptosis. Preliminary in vivo experiments are also performed and the consequences for a detailed in vivo study toward clinical translation are discussed. The combined PDT and deep‐tissue imaging properties of the nanomolecular PS present a large potential for future implementation into advanced in vivo photodynamic theranostics.

Source: crossref · Quality: baseline

Research context

Nanomaterials Biomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence Properties of Advanced Materials · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Univ Rouen, CNRS, INSA Rouen, Normandie Université Laboratoire COBRA Rouen 76000 France

Univ Angers, CNRS, MOLTECH‐ANJOU SFR MATRIX Angers 49000 France

Istituto di Chimica della Materia Condensata e Tecnologie per l'Energia (ICMATE) Consiglio Nazionale delle Ricerche (CNR) Padova 35131 Italy

Dipartimento di Scienze Chimiche Università di Padova Padova 35131 Italy

University of Grenoble Alpes, Institute for Advanced Biosciences INSERM‐U1209/CNRS‐UMR5309 Grenoble 38700 France

Univ Rennes CNRS UMR6226 Rennes F‐35042 France

Building Blocks for Future Electronics Laboratory (2BFUEL), IRL CNRS 2002 Yonsei University Seoul 03722 South Korea

Department of Chemistry Seoul National University Seoul 08826 South Korea

McMaster University Department of Engineering Physics Hamilton ON M8S 4K1 Canada

Funding

Région Normandie · Université de Rouen · Centre National de la Recherche Scientifique · European Regional Development Fund · Ministry of Science and ICT, South Korea · National Research Foundation of Korea · Canada Excellence Research Chairs, Government of Canada · Agence Nationale de la Recherche · H2020 Marie Skłodowska-Curie Actions

References (83)

Show source-provided references

1. 10.3322/caac.2011410.3322/caac.20114 ↗

2. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗

3. 10.1039/C8DT00087E10.1039/C8DT00087E ↗

4. 10.1021/cr900300p10.1021/cr900300p ↗

5. 10.1203/PDR.0b013e3181a9eafb10.1203/PDR.0b013e3181a9eafb ↗

6. 10.1021/acs.chemrev.5b0014010.1021/acs.chemrev.5b00140 ↗

7. 10.1021/acsami.7b1481210.1021/acsami.7b14812 ↗

8. 10.1002/adtp.20180010510.1002/adtp.201800105 ↗

9. 10.1039/D2TB02789E10.1039/D2TB02789E ↗

10. 10.1021/acsami.0c0436310.1021/acsami.0c04363 ↗

11. 10.1039/b003268i10.1039/b003268i ↗

12. 10.1016/B978‐0‐12‐407722‐5.00014‐110.1016/B978‐0‐12‐407722‐5.00014‐1 ↗

13. 10.1039/C8OB00421H10.1039/C8OB00421H ↗

14. 10.1021/acs.accounts.0c0060610.1021/acs.accounts.0c00606 ↗

15. 10.1039/D0SC04751A10.1039/D0SC04751A ↗

16. 10.1021/jacs.2c0343710.1021/jacs.2c03437 ↗

17. 10.1093/nar/gkad36510.1093/nar/gkad365 ↗

18. 10.1039/D0SC02286A10.1039/D0SC02286A ↗

19. 10.1039/D0SC04747C10.1039/D0SC04747C ↗

20. 10.1039/D2QM00299J10.1039/D2QM00299J ↗

21. 10.3390/colorants201000210.3390/colorants2010002 ↗

22. 10.1016/j.saa.2023.12368810.1016/j.saa.2023.123688 ↗

23. 10.1002/adfm.20211052610.1002/adfm.202110526 ↗

24. 10.1016/j.biomaterials.2022.12147610.1016/j.biomaterials.2022.121476 ↗

25. 10.1021/acsabm.2c0067510.1021/acsabm.2c00675 ↗

26. 10.1021/cr020357g10.1021/cr020357g ↗

27. 10.1021/cr400425h10.1021/cr400425h ↗

28. 10.1039/C4CS00177J10.1039/C4CS00177J ↗

29. 10.1039/C5CS90009C10.1039/C5CS90009C ↗

30. 10.1039/C4CS00158C10.1039/C4CS00158C ↗

31. 10.1021/acs.chemmater.7b0470010.1021/acs.chemmater.7b04700 ↗

32. 10.1088/2050-6120/ac693710.1088/2050-6120/ac6937 ↗

33. 10.1002/adhm.20210050610.1002/adhm.202100506 ↗

34. 10.1038/s41598-021-03978-210.1038/s41598-021-03978-2 ↗

35. 10.1016/j.cca.2021.10.02310.1016/j.cca.2021.10.023 ↗

36. 10.1021/nl104192910.1021/nl1041929 ↗

37. 10.1002/adom.20180141710.1002/adom.201801417 ↗

38. 10.1021/acs.nanolett.2c0489910.1021/acs.nanolett.2c04899 ↗

39. 10.1002/adfm.20220154110.1002/adfm.202201541 ↗

40. 10.1021/acsnano.7b0094410.1021/acsnano.7b00944 ↗

41. 10.1021/jz302122a10.1021/jz302122a ↗

42. 10.1039/C7NR02594G10.1039/C7NR02594G ↗

43. 10.1021/acsnano.2c1252310.1021/acsnano.2c12523 ↗

44. 10.1016/j.jre.2019.02.00110.1016/j.jre.2019.02.001 ↗

45. 10.1021/acs.chemrev.2c0041910.1021/acs.chemrev.2c00419 ↗

46. 10.1021/nn402601d10.1021/nn402601d ↗

47. 10.1039/C9TB01629E10.1039/C9TB01629E ↗

48. 10.7150/thno.528410.7150/thno.5284 ↗

49. 10.1002/adma.20210374810.1002/adma.202103748 ↗

50. 10.7150/thno.3017410.7150/thno.30174 ↗

51. 10.1126/sciadv.abb271210.1126/sciadv.abb2712 ↗

52. 10.1021/acs.chemmater.6b0329210.1021/acs.chemmater.6b03292 ↗

53. 10.1021/acs.orglett.0c0190310.1021/acs.orglett.0c01903 ↗

54. Hildebrandt N. · 2013

55. 10.1021/acsami.1c2349810.1021/acsami.1c23498 ↗

56. 10.1021/am503288d10.1021/am503288d ↗

57. 10.1021/acsnano.6b0255910.1021/acsnano.6b02559 ↗

58. 10.1039/C5NR03385C10.1039/C5NR03385C ↗

59. 10.1039/C4NR03833A10.1039/C4NR03833A ↗

60. 10.1002/anie.20150883810.1002/anie.201508838 ↗

61. 10.1039/c2nr32880a10.1039/c2nr32880a ↗

62. 10.1021/acsami.8b0776010.1021/acsami.8b07760 ↗

63. 10.1021/acs.nanolett.0c0332710.1021/acs.nanolett.0c03327 ↗

64. 10.1021/acs.est.8b0151210.1021/acs.est.8b01512 ↗

65. 10.1103/PhysRevB.4.315310.1103/PhysRevB.4.3153 ↗

66. 10.1002/adom.20130016010.1002/adom.201300160 ↗

67. 10.3390/cancers302251610.3390/cancers3022516 ↗

68. 10.1111/php.1285710.1111/php.12857 ↗

69. 10.1021/ja201919s10.1021/ja201919s ↗

70. 10.1039/C6CS00636A10.1039/C6CS00636A ↗

71. 10.1016/j.addr.2018.06.01310.1016/j.addr.2018.06.013 ↗

72. 10.1039/b926014p10.1039/b926014p ↗

73. 8 Key Takeaways Of The Proposed FDA Modernization Act 3.0 https://www.drugdiscoveryonline.com/doc/key‐takeaways‐of‐the‐proposed‐fda‐modernization‐act‐3‐0‐0001 (accessed: March 2024).

74. 10.1021/acsnano.7b0739310.1021/acsnano.7b07393 ↗

75. 10.1002/adhm.20190097210.1002/adhm.201900972 ↗

76. 10.1016/j.chempr.2021.03.00810.1016/j.chempr.2021.03.008 ↗

77. 10.1089/pho.2012.328410.1089/pho.2012.3284 ↗

78. 10.1142/S179354581743002710.1142/S1793545817430027 ↗

79. 10.1186/1471-230X-9-6410.1186/1471-230X-9-64 ↗

80. 10.1021/jacs.8b0708610.1021/jacs.8b07086 ↗

81. 10.1039/D0NR04357E10.1039/D0NR04357E ↗

82. 10.1016/j.jcis.2023.06.03410.1016/j.jcis.2023.06.034 ↗

83. 10.1039/c2ce26159f10.1039/c2ce26159f ↗